NCT03372837 - Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Interventions

DRUG

Rituximab

The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.

Trial Locations (29)

Unknown

Research Site, Nagoya

Research Site, Toyoake

Research Site, Matsuyama

Research Site, Maebashi

Research Site, Ōta

Research Site, Shibukawa

Research Site, Fukuyama

Research Site, Sapporo

Research Site, Kobe

Research Site, Isehara

Research Site, Sendai

Research Site, Sayama

Research Site, Izumo

Research Site, Mibu

Research Site, Shimotsuke

Research Site, Chuo-ku

Research Site, Koto-ku

Research Site, Shibuya-ku

Research Site, Shinagawa-ku

Research Site, Akita

Research Site, Fukuoka

Research Site, Fukushima

Research Site, Ibaraki

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Nagasaki

Research Site, Okayama

Research Site, Osaka

Research Site, Yamagata